HK1166308A1 - 激活酶抑制劑 - Google Patents
激活酶抑制劑Info
- Publication number
- HK1166308A1 HK1166308A1 HK12106507.9A HK12106507A HK1166308A1 HK 1166308 A1 HK1166308 A1 HK 1166308A1 HK 12106507 A HK12106507 A HK 12106507A HK 1166308 A1 HK1166308 A1 HK 1166308A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- inhibitors
- activating enzymes
- enzymes
- activating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Epoxy Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76448706P | 2006-02-02 | 2006-02-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1166308A1 true HK1166308A1 (zh) | 2012-10-26 |
Family
ID=38180115
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK12106507.9A HK1166308A1 (zh) | 2006-02-02 | 2009-04-27 | 激活酶抑制劑 |
HK09103865.7A HK1124609A1 (en) | 2006-02-02 | 2009-04-27 | Inhibitors of e1 activating enzyme e1 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09103865.7A HK1124609A1 (en) | 2006-02-02 | 2009-04-27 | Inhibitors of e1 activating enzyme e1 |
Country Status (28)
Country | Link |
---|---|
US (6) | US8207177B2 (zh) |
EP (2) | EP2402334B1 (zh) |
JP (6) | JP5231251B2 (zh) |
KR (2) | KR101450533B1 (zh) |
CN (4) | CN101379061B (zh) |
AR (1) | AR059308A1 (zh) |
AU (1) | AU2007212648C1 (zh) |
BR (1) | BRPI0707493B8 (zh) |
CA (1) | CA2639924C (zh) |
CY (1) | CY1113114T1 (zh) |
DK (1) | DK1989206T3 (zh) |
EA (2) | EA024006B1 (zh) |
ES (2) | ES2593433T3 (zh) |
HK (2) | HK1166308A1 (zh) |
HR (1) | HRP20120786T1 (zh) |
IL (2) | IL193141A (zh) |
MY (2) | MY171289A (zh) |
NO (1) | NO342745B1 (zh) |
NZ (1) | NZ570084A (zh) |
PH (1) | PH12013501772A1 (zh) |
PL (1) | PL1989206T3 (zh) |
PT (1) | PT1989206E (zh) |
RS (1) | RS52437B (zh) |
SG (1) | SG169369A1 (zh) |
SI (1) | SI1989206T1 (zh) |
TW (2) | TWI510486B (zh) |
WO (1) | WO2007092213A2 (zh) |
ZA (1) | ZA200806402B (zh) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GT200500281A (es) * | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0500785D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
CN101379061B (zh) * | 2006-02-02 | 2016-06-15 | 千禧药品公司 | E1活化酶抑制剂 |
GB0607945D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607944D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
AR060607A1 (es) * | 2006-04-21 | 2008-07-02 | Novartis Ag | Derivados de purina,composiciones farmaceuticas que los contienen, metodo de preparacion y usos en enfermedades obstructivas o inflamatorias de las vias respiratorias. |
GB0607953D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607948D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607950D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
EP1889846A1 (en) | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
ZA200900670B (en) * | 2006-08-08 | 2010-04-28 | Millennium Pharm Inc | Heteroaryl compounds useful as inhititors of E1 activating enzymes |
US8008307B2 (en) | 2006-08-08 | 2011-08-30 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of E1 activating enzymes |
EP1903044A1 (en) * | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
RU2009121819A (ru) * | 2006-11-10 | 2010-12-20 | Новартис АГ (CH) | Производные моноацетата циклопентендиола |
US8933225B2 (en) * | 2007-08-02 | 2015-01-13 | Millennium Pharmaceuticals, Inc. | Process for the synthesis of E1 activating enzyme inhibitors |
AU2013204618B2 (en) * | 2007-08-02 | 2015-11-05 | Takeda Pharmaceutical Company Limited | Process for the synthesis of E1 activating enzyme inhibitors |
AU2008313789A1 (en) * | 2007-10-17 | 2009-04-23 | Novartis Ag | Purine derivatives as adenosine AL receptor ligands |
US20110237606A1 (en) * | 2008-09-26 | 2011-09-29 | Agency Of Science, Technology And Research | 3-Deazaneplanocin Derivatives |
UA104010C2 (en) * | 2008-12-18 | 2013-12-25 | Эли Лилли Энд Компани | Purine compounds |
EP2430026A1 (en) * | 2009-05-14 | 2012-03-21 | Millennium Pharmaceuticals, Inc. | Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate |
WO2012061551A1 (en) * | 2010-11-05 | 2012-05-10 | Millennium Pharmaceuticals, Inc. | Administration of nedd8-activating enzyme inhibitor |
EP2646454B1 (en) | 2010-12-03 | 2015-07-08 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
WO2012075492A2 (en) * | 2010-12-03 | 2012-06-07 | Epizyme, Inc. | Carbocycle-substituted purine and 7-deazapurine compounds |
RU2606514C2 (ru) | 2010-12-03 | 2017-01-10 | Эпизайм, Инк. | Замещенные пуриновые и 7-деазапуриновые соединения |
CA2823935A1 (en) | 2011-01-07 | 2012-07-12 | Leo Pharma A/S | Novel sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof |
WO2012158789A2 (en) | 2011-05-17 | 2012-11-22 | St. Jude Children's Research Hospital | Methods and compositions for inhibiting neddylation of proteins |
KR101230678B1 (ko) | 2011-06-22 | 2013-02-07 | 이화여자대학교 산학협력단 | E1 활성화 억제제인 mln4924의 제조방법 |
AU2012298813B2 (en) * | 2011-08-24 | 2016-07-28 | Millennium Pharmaceuticals, Inc. | Inhibitors of Nedd8-activating enzyme |
WO2013052814A2 (en) * | 2011-10-07 | 2013-04-11 | Millennium Pharmaceuticals, Inc. | E1 enzyme mutants and uses thereof |
JP6238900B2 (ja) | 2011-10-28 | 2017-11-29 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | Nae阻害物質に対する応答のバイオマーカー |
MX357835B (es) | 2011-11-03 | 2018-07-26 | Millennium Pharm Inc | Administración de inhibidor de enzimas que activa nedd8 y agente de hipometilación. |
KR20140123104A (ko) * | 2012-02-17 | 2014-10-21 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 유비퀴틴 활성화 효소의 피라졸로피리미디닐 억제제 |
CN104684559A (zh) * | 2012-08-03 | 2015-06-03 | 米伦纽姆医药公司 | 针对Uba6的吲哚取代的吡咯并嘧啶基抑制剂 |
WO2014026198A1 (en) | 2012-08-10 | 2014-02-13 | Epizyme, Inc. | Inhibitors of protein methyltransferase dot1l and methods of use thereof |
WO2014039839A1 (en) | 2012-09-06 | 2014-03-13 | Epizyme, Inc. | Method of treating leukemia |
CN104822844B (zh) | 2012-10-01 | 2019-05-07 | 米伦纽姆医药公司 | 预测对抑制剂的反应的生物标记物和方法以及其用途 |
CA2903303A1 (en) | 2013-03-15 | 2014-09-25 | Epizyme, Inc. | Methods of synthesizing substituted purine compounds |
EP2996773B1 (en) | 2013-05-14 | 2020-09-16 | Millennium Pharmaceuticals, Inc. | Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents |
WO2015002994A2 (en) * | 2013-07-02 | 2015-01-08 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of sumo activating enzyme |
WO2015013256A1 (en) * | 2013-07-22 | 2015-01-29 | Baylor College Of Medicine | Non-ribose containing inhibitors of histone methyltransferase dot1l for cancer treatment |
CA2946833C (en) | 2014-06-24 | 2019-03-05 | Taiho Pharmaceutical Co., Ltd. | Pyrrolopyrimidine compounds for prevention of tumors based on nae inhibitory effect |
DK3164130T3 (da) | 2014-07-01 | 2019-10-28 | Millennium Pharm Inc | Heteroaryle forbindelser anvendelige som inhibatorer af sumo-aktiverende enzym |
TW201625256A (zh) * | 2014-10-29 | 2016-07-16 | 千禧製藥公司 | 泛素活化酶抑制劑及化療劑之投藥 |
EA037663B1 (ru) | 2015-01-16 | 2021-04-28 | Те Дженерал Хоспитал Корпорейшн | СОЕДИНЕНИЯ ДЛЯ УЛУЧШЕНИЯ СПЛАЙСИНГА мРНК |
TW201639811A (zh) | 2015-03-13 | 2016-11-16 | 佛瑪治療公司 | 作為HDAC8抑制劑之α-桂皮醯胺化合物與組成物 |
CN105541810B (zh) * | 2016-03-04 | 2019-05-17 | 南京工业大学 | 一种香豆素类nedd8激活酶抑制剂及其制备方法与应用 |
WO2017183927A1 (ko) * | 2016-04-20 | 2017-10-26 | 한국화학연구원 | 신규한 헤테로고리 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
CN106008394B (zh) * | 2016-05-23 | 2018-12-04 | 中国人民解放军第二军医大学 | 巯基苯并噻唑酰胺类化合物及其制备与作为药物的用途 |
CN106854208B (zh) * | 2016-11-25 | 2019-04-09 | 成都柏睿泰生物科技有限公司 | 肿瘤抑制剂mln4924的合成方法 |
US11124519B2 (en) | 2017-09-21 | 2021-09-21 | Millennium Pharmaceuticals, Inc. | Cocrystal forms of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl) methyl sulfamate, formulations and uses thereof |
US20200377958A1 (en) | 2017-12-01 | 2020-12-03 | Millennium Pharmaceuticals, Inc. | Biomarkers and methods for treatment with nae inhibitors |
EP3787663A4 (en) * | 2018-05-03 | 2022-03-09 | Her Majesty The Queen In Right of Canada as represented by The Minister of Health | SMALLPOXVIRUS HOST ZONE PROTEIN K3 AS A POSITIVE SELECTIVE MARKER FOR GENERATING RECOMBINANT SMALLPOXVIRUS, THERAPEUTIC TARGET FOR SMALLPOXVIRUS INFECTION AND THERAPEUTIC AGENT FOR PKR-RELATED DISEASES |
US20210267972A1 (en) * | 2018-07-09 | 2021-09-02 | Millennium Pharmaceuticals, Inc. | Administration of sumo-activating enzyme inhibitor and anti-cd20 antibodies |
EP3820533A2 (en) * | 2018-07-13 | 2021-05-19 | IL-2RX, Inc. | Compounds, compositions, methods, and uses for treating cancer and immunological disorders |
CN110229067A (zh) * | 2019-06-05 | 2019-09-13 | 南京焕然生物科技有限公司 | 一种2-氨基茚制备方法 |
CN112079836B (zh) * | 2019-06-13 | 2022-12-13 | 中国科学院上海药物研究所 | 三唑并嘧啶类化合物及其盐、组合物和应用 |
WO2021168446A1 (en) * | 2020-02-21 | 2021-08-26 | Mitokinin, Inc. | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease |
CA3192055A1 (en) | 2020-08-18 | 2022-02-24 | Incyte Corporation | Process and intermediates for preparing a jak1 inhibitor |
US11905292B2 (en) | 2020-08-18 | 2024-02-20 | Incyte Corporation | Process and intermediates for preparing a JAK inhibitor |
WO2022112951A1 (en) | 2020-11-25 | 2022-06-02 | Takeda Pharmaceutical Company Limited | Solid state forms of hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate |
CN112679505B (zh) * | 2020-12-25 | 2022-04-22 | 杭州澳赛诺生物科技有限公司 | 一种4-甲基-7H-吡咯并[2,3-d]嘧啶的合成方法 |
CN112851671B (zh) * | 2021-02-08 | 2022-03-29 | 南京思聚生物医药有限公司 | 一种4-取代的吡啶并[2,3-d]嘧啶-7-酮类化合物及其制备方法和应用 |
CN112939971B (zh) * | 2021-02-08 | 2023-01-24 | 南京易腾药物研究院有限公司 | 一种香豆素类化合物及其制备方法和应用 |
WO2023023671A1 (en) * | 2021-08-20 | 2023-02-23 | Mitokinin, Inc. | Compositions and methods for treatment of neurodegenerative and mitochondrial disease |
WO2023025668A1 (en) | 2021-08-25 | 2023-03-02 | Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune | Methods for the generation of stem cell memory t cells for adoptive t cell therapy |
WO2024067676A1 (zh) * | 2022-09-30 | 2024-04-04 | 微境生物医药科技(上海)有限公司 | 作为sumo活化酶抑制剂的化合物 |
WO2024099438A1 (zh) * | 2022-11-11 | 2024-05-16 | 微境生物医药科技(上海)有限公司 | 作为sumo活化酶抑制剂的化合物 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3622561A (en) * | 1969-08-18 | 1971-11-23 | Univ Utah | Nucleoside sugar esters of sulfamic acid and method for preparation of the same |
JPS62108897A (ja) | 1985-11-05 | 1987-05-20 | Rikagaku Kenkyusho | アスカマイシン誘導体及びその合成法並びに制癌剤 |
GB8813148D0 (en) | 1988-06-03 | 1988-07-06 | Glaxo Group Ltd | Chemical compounds |
GB8826205D0 (en) * | 1988-11-09 | 1988-12-14 | Wellcome Found | Heterocyclic compounds |
US5864033A (en) * | 1989-09-15 | 1999-01-26 | Metabasis Therapeutics, Inc. | Adenosine kinase inhibitors |
US5726302A (en) * | 1989-09-15 | 1998-03-10 | Gensia Inc. | Water soluble adenosine kinase inhibitors |
US5721356A (en) | 1989-09-15 | 1998-02-24 | Gensia, Inc. | Orally active adenosine kinase inhibitors |
US5763596A (en) * | 1989-09-15 | 1998-06-09 | Metabasis Therapeutics, Inc. | C-4' modified adenosine kinase inhibitors |
US5674998A (en) | 1989-09-15 | 1997-10-07 | Gensia Inc. | C-4' modified adenosine kinase inhibitors |
GB9325809D0 (en) | 1993-12-17 | 1994-02-23 | Zeneca Ltd | Herbicidal composition |
GB9325810D0 (en) | 1993-12-17 | 1994-02-23 | Zeneca Ltd | Herbicidal composition |
US6210917B1 (en) * | 1993-12-29 | 2001-04-03 | The Regents Of The University Of California | Method for suppressing multiple drug resistance in cancer cells |
US5767097A (en) * | 1996-01-23 | 1998-06-16 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes |
US5973161A (en) * | 1996-03-18 | 1999-10-26 | The University Of North Carolina At Chapel Hill | Enantioselective synthesis of cyclopentenes |
US5824657A (en) * | 1997-03-18 | 1998-10-20 | Cubist Pharmaceuticals, Inc. | Aminoacyl sulfamides for the treatment of hyperproliferative disorders |
US6734283B1 (en) * | 1997-12-19 | 2004-05-11 | Millennium Pharmaceuticals, Inc. | Human proteins responsible for NEDD8 activation and conjugation |
JPH11228422A (ja) | 1998-02-16 | 1999-08-24 | Mitsubishi Chemical Corp | 抗マラリア剤 |
JPH11228446A (ja) | 1998-02-16 | 1999-08-24 | Mitsubishi Chemical Corp | 抗マラリア剤 |
KR101005299B1 (ko) * | 2000-10-18 | 2011-01-04 | 파마셋 인코포레이티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드 |
EP1474147B1 (en) | 2001-12-07 | 2010-05-05 | Vertex Pharmaceuticals Incorporated | Pyrimidine-based compounds useful as gsk-3 inhibitors |
AU2003248708A1 (en) | 2002-06-17 | 2003-12-31 | Isis Pharmaceuticals, Inc. | Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation |
US7915293B2 (en) * | 2003-05-30 | 2011-03-29 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
WO2005037845A1 (en) | 2003-10-17 | 2005-04-28 | Rigel Pharmaceuticals, Inc. | Benzothiazole and thiazole[5,5-b] pyridine compositions and their use as ubiquitin ligase inhibitors |
EP1758873A1 (en) * | 2004-06-22 | 2007-03-07 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
CA2596424C (en) * | 2005-02-04 | 2016-03-29 | Millennium Pharmaceuticals, Inc. | Inhibitors of e1 activating enzymes |
CN101379061B (zh) * | 2006-02-02 | 2016-06-15 | 千禧药品公司 | E1活化酶抑制剂 |
-
2007
- 2007-01-31 CN CN200780004410.1A patent/CN101379061B/zh active Active
- 2007-01-31 US US11/700,614 patent/US8207177B2/en active Active - Reinstated
- 2007-01-31 EA EA200801784A patent/EA024006B1/ru not_active IP Right Cessation
- 2007-01-31 JP JP2008553310A patent/JP5231251B2/ja not_active Expired - Fee Related
- 2007-01-31 RS RS20120419A patent/RS52437B/en unknown
- 2007-01-31 PL PL07763239T patent/PL1989206T3/pl unknown
- 2007-01-31 PT PT07763239T patent/PT1989206E/pt unknown
- 2007-01-31 CN CN201610326315.4A patent/CN106008512B/zh active Active
- 2007-01-31 CA CA2639924A patent/CA2639924C/en not_active Expired - Fee Related
- 2007-01-31 CN CN201910117672.3A patent/CN110003216A/zh active Pending
- 2007-01-31 ES ES11166220.1T patent/ES2593433T3/es active Active
- 2007-01-31 MY MYPI2013003308A patent/MY171289A/en unknown
- 2007-01-31 EA EA201500769A patent/EA031335B1/ru not_active IP Right Cessation
- 2007-01-31 AU AU2007212648A patent/AU2007212648C1/en not_active Ceased
- 2007-01-31 BR BRPI0707493A patent/BRPI0707493B8/pt not_active IP Right Cessation
- 2007-01-31 DK DK07763239.6T patent/DK1989206T3/da active
- 2007-01-31 ES ES07763239T patent/ES2390921T3/es active Active
- 2007-01-31 EP EP11166220.1A patent/EP2402334B1/en active Active
- 2007-01-31 KR KR1020087020864A patent/KR101450533B1/ko active IP Right Grant
- 2007-01-31 KR KR1020147008025A patent/KR101450535B1/ko active IP Right Grant
- 2007-01-31 CN CN2013101694424A patent/CN103288835A/zh active Pending
- 2007-01-31 SG SG201100750-7A patent/SG169369A1/en unknown
- 2007-01-31 EP EP07763239A patent/EP1989206B1/en active Active
- 2007-01-31 MY MYPI20082915A patent/MY158106A/en unknown
- 2007-01-31 WO PCT/US2007/002560 patent/WO2007092213A2/en active Application Filing
- 2007-01-31 SI SI200731029T patent/SI1989206T1/sl unknown
- 2007-01-31 NZ NZ570084A patent/NZ570084A/en not_active IP Right Cessation
- 2007-02-02 TW TW096103917A patent/TWI510486B/zh not_active IP Right Cessation
- 2007-02-02 AR ARP070100458A patent/AR059308A1/es active IP Right Grant
- 2007-02-02 TW TW103118125A patent/TW201509938A/zh unknown
-
2008
- 2008-07-23 ZA ZA2008/06402A patent/ZA200806402B/en unknown
- 2008-07-30 IL IL193141A patent/IL193141A/en active IP Right Grant
- 2008-08-19 NO NO20083581A patent/NO342745B1/no not_active IP Right Cessation
-
2009
- 2009-04-27 HK HK12106507.9A patent/HK1166308A1/zh not_active IP Right Cessation
- 2009-04-27 HK HK09103865.7A patent/HK1124609A1/xx not_active IP Right Cessation
-
2012
- 2012-06-19 US US13/526,946 patent/US20120258927A1/en not_active Abandoned
- 2012-06-19 US US13/527,018 patent/US20130165457A9/en not_active Abandoned
- 2012-09-28 CY CY20121100890T patent/CY1113114T1/el unknown
- 2012-10-02 HR HRP20120786TT patent/HRP20120786T1/hr unknown
-
2013
- 2013-02-15 JP JP2013027485A patent/JP2013103941A/ja not_active Withdrawn
- 2013-03-14 US US13/828,953 patent/US20130289037A1/en not_active Abandoned
- 2013-08-27 PH PH12013501772A patent/PH12013501772A1/en unknown
-
2014
- 2014-05-25 IL IL232786A patent/IL232786A/en active IP Right Grant
- 2014-11-26 JP JP2014238578A patent/JP6199851B2/ja not_active Expired - Fee Related
-
2016
- 2016-05-24 JP JP2016103009A patent/JP2016147913A/ja not_active Withdrawn
- 2016-07-20 US US15/214,930 patent/US20170136024A1/en not_active Abandoned
-
2017
- 2017-11-24 JP JP2017225707A patent/JP2018027986A/ja not_active Withdrawn
-
2018
- 2018-09-19 US US16/135,380 patent/US20190255052A1/en not_active Abandoned
-
2019
- 2019-12-04 JP JP2019219430A patent/JP2020055841A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL232786A0 (en) | Inhibitors of e1 enzyme activators | |
ME02012B (me) | INHIBITORI El AKTIVIRAJUĆIH ENZIMA | |
IL254784A0 (en) | Heteroaryl compounds for use as inhibitors of e1-activating enzymes | |
GB0619753D0 (en) | Enzyme inhibitors | |
ZA200807135B (en) | Azolopyridin-3-one derivatives as inhibitors of endothelial lipase | |
EP2026843A4 (en) | THERAPEUTIC USES OF RTP801L INHIBITORS | |
IL194339A0 (en) | Enzyme inhibitors | |
HK1129298A1 (zh) | 可用作蛋白激酶抑制劑的二氫二氮雜䓬 | |
IL195031A0 (en) | Uses of dpp-iv inhibitors | |
HK1137758A1 (en) | Inhibitors of akt activity akt | |
ZA200706345B (en) | Amino-pyridines as inhibitors of ß-secretase | |
IL194699A0 (en) | Tetrahydropteridines useful as inhibitors of protein kinases | |
EP2047864A4 (en) | USE OF INHIBITOR OF RPN2 GENE EXPRESSION | |
ZA200806871B (en) | Dihydrodiazepines useful as inhibitors of protein kinases | |
EP2120951A4 (en) | INHIBITORS OF AKT ACTIVITY | |
GB0608844D0 (en) | Enzyme inhibitors | |
GB0617161D0 (en) | Enzyme inhibitors | |
EP2067859A4 (en) | USE OF AN ACTIVATED CYTOKININ BIOSYNTHETIZING ENZYME | |
IL198803A0 (en) | Selective inhibitors of neurotensin degrading enzymes | |
GB0608855D0 (en) | Inhibitors of MAP kinase enzymes | |
GB0621283D0 (en) | Inhibitors of PLK Enzymes | |
GB0620884D0 (en) | Enzyme inhibitors | |
GB0612544D0 (en) | Enzyme inhibitors | |
GB0624958D0 (en) | Enzyme inhibitors | |
ZA200808237B (en) | Enzyme inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20220130 |